Characterization of orofacial features in sclerodermatous chronic graft-versus-host disease

被引:1
|
作者
Bajonaid, Amal [1 ,12 ]
Guntaka, Praveen Kumar [2 ]
Harper, Matthew [3 ,4 ]
Cutler, Corey [5 ]
Duncan, Christine [6 ]
Villa, Alessandro [7 ,8 ,9 ]
Sroussi, Herve Y. [10 ,11 ]
Woo, Sook-Bin [10 ,11 ]
Treister, Nathaniel S. [10 ,11 ]
机构
[1] Jazan Univ, Coll Dent, Jazan, Saudi Arabia
[2] Mt Sinai Hlth Syst, New York, NY USA
[3] Harvard Sch Dent Med, Dept Dev Biol, Boston, MA USA
[4] Boston Childrens Hosp, Dept Dent, Boston, MA USA
[5] Dana Farber Canc Inst, Div Stem Cell Transplantat & Cellular Therapy, Boston, MA USA
[6] Dana Farber Boston Childrens Canc & Blood Disorder, Boston, MA USA
[7] Univ Calif San Francisco, Dept Orofacial Sci, San Francisco, CA USA
[8] Herbert Wertheim Coll Med, Miami, FL USA
[9] Miami Canc Inst, Miami, FL USA
[10] Harvard Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA USA
[11] Brigham & Womens Hosp, Div Oral Med & Dent, Boston, MA USA
[12] Jazan Univ, Coll Dent, Dept Oral & Maxillofacial Surg & Diagnost Sci, Al Maarefah Rd, Jazan, Saudi Arabia
关键词
face; graft-versus-host disease; oral cavity; sclerosis; CONSENSUS DEVELOPMENT PROJECT; RISK-FACTORS; PHOTOBIOMODULATION THERAPY; CELL TRANSPLANTATION; ORAL INVOLVEMENT; CLINICAL-TRIALS; CHRONIC GVHD; RECOMMENDATIONS; CRITERIA; PATHOGENESIS;
D O I
10.1111/odi.14932
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
BackgroundChronic graft-versus-host disease (cGVHD) is a leading cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (alloHCT). The sclerodermatous form of cGVHD can be particularly debilitating; however, orofacial sclerodermatous involvement remains poorly described. ObjectiveTo characterize orofacial features of sclerodermatous cGVHD in a single center cohort of patients who underwent alloHCT. Study DesignRetrospective data were collected from electronic medical records and analyzed descriptively. ResultsThere were 39 patients who received alloHCT between 1993 and 2017 and developed orofacial sclerodermatous cGVHD. Concomitant cutaneous sclerodermatous cGVHD was common (n = 20, 51%). Orofacial sclerodermatous cGVHD features included fibrous bands of the buccal mucosa (n = 23, 59%), limited mouth opening (n = 19, 54%), perioral fibrosis (n = 8, 21%), and focal gingival recession (n = 4, 10%). Oral mucosal fibrosis was observed at the site of active or resolved chronic lichenoid inflammation in 30 patients, with all but two also presenting with a history of ulcerations. Management included jaw stretching exercises (n = 10; 6 stable/improved), surgery (n = 3; 2 improved), and intralesional corticosteroid injections (n = 2; 2 improved). ConclusionsOrofacial involvement with sclerodermatous cGVHD can present with multiple manifestations including fibrous banding, limited mouth opening, perioral fibrosis, and focal gingival recession. Surgical and non-surgical management strategies may improve clinical function and reduce morbidity.
引用
收藏
页码:5082 / 5090
页数:9
相关论文
共 50 条
  • [21] Kinetics of circulating endothelial progenitors in patients with sclerodermatous chronic graft-versus-host disease
    Ahihara, Eishi
    Shimura, Kazuho
    Shimazaki, Chihiro
    Matsunaga, Shinsaku
    Tanaka, Ruriko
    Yokota, Asumi
    Murotani, Yoshihide
    Takeuchi, Miki
    Kawata, Eri
    Kamitsuji, Yuri
    Kuroda, Junya
    Taniwaki, Masafumi
    Kimura, Shinya
    Maekawa, Taira
    BLOOD, 2007, 110 (11) : 326A - 327A
  • [22] Treatment of refractory sclerodermatous chronic graft-versus-host disease with intravenous lidocaine infusions
    Phipps, C.
    Lupo-Stanghellini, M. T.
    Flowers, M. E. D.
    BONE MARROW TRANSPLANTATION, 2014, 49 (02) : 315 - 316
  • [23] Blockade of Syk Ameliorates the Development of Sclerodermatous Chronic Graft-Versus-Host Disease.
    Matsushita, T.
    Le Huu, D.
    Kimura, H.
    Date, M.
    Hamaguchi, Y.
    Hasegawa, M.
    Fujimoto, M.
    Takehara, K.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 : S3 - S3
  • [24] Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease
    M Okamoto
    A Okano
    S Akamatsu
    E Ashihara
    T Inaba
    H Takenaka
    N Katoh
    S Kishimoto
    C Shimazaki
    Leukemia, 2006, 20 : 172 - 173
  • [25] Treatment of refractory sclerodermatous chronic graft-versus-host disease with intravenous lidocaine infusions
    C Phipps
    M T Lupo-Stanghellini
    M E D Flowers
    Bone Marrow Transplantation, 2014, 49 : 315 - 316
  • [26] Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease
    Okamoto, M
    Okano, A
    Akamatsu, S
    Ashihara, E
    Inaba, T
    Takenaka, H
    Katoh, N
    Kishimoto, S
    Shimazaki, C
    LEUKEMIA, 2006, 20 (01) : 172 - 173
  • [27] Efficacy of Imatinib Mesylate in the Treatment of Refractory Sclerodermatous Chronic Graft-Versus-Host Disease
    Yakoub-Agha, Ibrahim
    Magro, Leonardo
    Catteau, Benoit
    Willekens, Christophe
    Coiteux, Valerie
    Bruno, Benedicte
    Terriou, Louis
    Jouet, Jean-Pierre
    BLOOD, 2008, 112 (11) : 745 - 746
  • [28] Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease
    Doanh Le Huu
    Kimura, Hiroshi
    Date, Mutsumi
    Hamaguchi, Yasuhito
    Hasegawa, Minoru
    Khang Tran Hau
    Fujimoto, Manabu
    Takehara, Kazuhiko
    Matsushita, Takashi
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2014, 74 (03) : 214 - 221
  • [29] Imatinib for sclerodermatous graft-versus-host disease in lung transplantation
    Zhang, Jitian
    Chen, Fengshi
    Ueki, Toshimitsu
    Date, Hiroshi
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2015, 21 (02) : 260 - 262
  • [30] Improvement of Sclerodermatous Graft-Versus-Host Disease in Mice by Niclosamide
    Morin, Florence
    Kavian, Niloufar
    Nicco, Carole
    Cerles, Olivier
    Chereau, Christiane
    Batteux, Frederic
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (11) : 2158 - 2167